Author

M. Sokolsky-Papkov

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cancer & tumor microenvironment· 3 Research Focus:drug response / drug discovery· 3 Organism:mouse· 3 Research Focus:benchmarking· 1 Research Focus:host-pathogen & immune response· 1 Organism:non-human primate· 1 Assay:organoid / primary culture· 1

Frequent Co-Authors

C. Lim· 3 shared D. Hwang· 3 shared A. V. Kabanov· 2 shared J. D. Ramsey· 2 shared N. Vinod· 2 shared A. E. D. Van Swearingen· 1 shared A. Kabanov· 1 shared B. W. Day· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C. Lim

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

High-Dose Paclitaxel and its Combination with CSF1R Inhibitor in Polymeric Micelles for Chemoimmunotherapy of Triple Negative Breast Cancer

C. Lim, D. Hwang, M. Yazdimamaghani, H. M. Atkins, H. Hyun, Y. Shin, J. D. Ramsey, C. M. Perou, M. Sokolsky-Papkov, A. Kabanov

This study evaluates high-dose paclitaxel and its combination with CSF1R inhibitor in polymeric micelles for chemoimmunotherapy of triple-negative breast cancer, showing improved therapeutic outcomes and immune response.

bioRxiv · Aug 12, 2022Cancer Biology

Targeting OLIG2 increases therapeutic responses in SHH medulloblastoma mouse models and patient-derived medulloblastoma organoids

Y. Li, T. Dismuke, C. Lim, Z. C. Bruce, C. Offenhauser, U. Baumgartner, M. Maybury, R. C. J. DSouza, T. Hassall, B. Wainwright, G. Stein, M. Piper, T. G. Johns, M. Sokolsky-Papkov, T. R. Gershon, B. W. Day

This study shows that targeting OLIG2 with CT-179 reduces recurrence in SHH medulloblastoma models and improves survival when combined with radiotherapy.

bioRxiv · Feb 14, 2022 · PreprintCancer Biology

Bioequivalence Assessment of High-Capacity Polymeric Micelle Nanoformulation of Paclitaxel and Abraxane(R) in Rodent and Non-Human Primate Models Using a Stable Isotope Tracer Assay

D. Hwang, N. Vinod, S. L. Skoczen, J. D. Ramsey, K. S. Snapp, S. A. Montgomery, M. Wang, C. Lim, J. E. Frank, M. Sokolsky-Papkov, Z. Li, H. Yuan, S. T. Stern, A. V. Kabanov

Biomaterials · Nov 1, 2021Peer-reviewedPharmacology & Toxicology

High Capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of Lung Adenocarcinoma

N. Vinod, D. Hwang, S. H. Azam, A. E. D. Van Swearingen, E. Wayne, S. C. Fussell, M. Sokolsky-Papkov, C. V. Pecot, A. V. Kabanov

This study shows that a novel nanomicellar formulation of Resiquimod extends survival in a metastatic lung adenocarcinoma model more effectively than chemotherapy and anti-PD1 therapy.

bioRxiv · Dec 12, 2019Pharmacology & Toxicology